Development-Driven CDMOs: The Future of Your Pharmaceutical Success
About This Webcast
In an increasingly complex pharmaceutical landscape, companies face significant challenges in bringing their products from development to market efficiently and seamlessly. The fragmentation of CDMO services, lack of integration between development and manufacturing, and uncertainties in cost and technical feasibility often lead to delays, increased risks, and higher expenses. How can pharmaceutical companies secure a streamlined, reliable, and cost-effective pathway from early development to commercial production? This webinar aims to answer that question by presenting Fareva’s unique approach as an end-to-end CDMO. With a fully integrated offering, Fareva eliminates the traditional hurdles of fragmented outsourcing by ensuring a seamless transition from pharmaceutical development to industrial-scale manufacturing. Our three GMP pilot sites support product development and technical transfers across fifteen manufacturing facilities, providing a structured and predictable process for our clients. By aligning development and manufacturing from the outset, we simplify project management with a single point of contact, ensure cost visibility, and accelerate time-to-market. The session will also highlight Fareva’s specialized expertise in high-potency oral solid doses, sterile manufacturing, and biologics, demonstrating how our tailored solutions can support even the most complex pharmaceutical developments. We will explore real-world examples, including how we successfully transferred an mRNA vaccine in record time, overcoming major technical challenges with speed and precision. Through this presentation, you will gain a clearer understanding of how working with a development-driven CDMO can mitigate risks, optimize resources, and ensure a successful pathway to commercialization.
Speakers
Philippe Rampignon
VP Pharmaceutical R&D , Fareva
With over 25 years of experience in the pharmaceutical industry, Philippe Rampignon currently serves as Vice President of Pharmaceutical R&D at Fareva, which he joined five years ago. He oversees pharmaceutical development and technology transfers within the Pharma BU. A Doctor of Pharmacy specializing in process industrialization, he has built his career within both local and global organizations, evolving in demanding environments at Schering-Plough, Abbott, GSK Pharma, Guerbet, GSK Vaccines, and Sanofi. His expertise spans injectable and inhaled products (MDI & DPI), with recognition as a Subject Matter Expert in these fields. He has also led global change management for an inhaled product portfolio and spearheaded industrial projects dedicated to the sterile filling of intravenous bags and vials. His career has led him to hold strategic leadership roles, notably as Director of Business Process Improvement, where he oversaw the lifecycle management of vaccine products on a global scale. He excels in defining strategies aligned with corporate objectives, developing integrated models from proof of concept to commercial scale, as well as project management and change leadership. Today, at Fareva, Philippe Rampignon leverages his expertise to structure and energize pharmaceutical R&D, ensuring the development of innovative solutions and supporting the transformation of projects to an industrial scale.
Aude Rémond
Corporate Quality Director , BU Pharma & API Fareva
A Doctor of Pharmacy with a University Diploma in Quality Control, Aude Rémond has extensive expertise in quality management and regulatory compliance. She has held successive positions as Quality Director, Quality Assurance Manager, and Quality Control Manager in several pharmaceutical laboratories, primarily in the contract manufacturing sector. With significant experience in managing inspections and maintaining compliance at industrial sites, she supports the transformation of production facilities through the introduction of new projects and products, as well as the modernization of infrastructures. Her rigorous and strategic approach ensures operational excellence and adherence to the highest standards in the pharmaceutical industry. Today, as Corporate Quality Director for the Pharma & API BU at Fareva Corporate France, she oversees quality-related challenges at the group level, actively contributing to the success of projects and the long-term sustainability of excellence standards across industrial sites.
Kristin Brooks
Managing Editor , Contract Pharma
Kristin Brooks is Managing Editor at Contract Pharma, where Kristin develops and creates content for the brand, including the magazine, website and social media channels, covering pharmaceutical and biopharmaceutical outsourcing and industry trends.